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I magine training the body to attack cancer.  As de-fined by the National Cancer Institute, cancer is a process by which abnormal cells divide without 
control and are able to invade other tissues.1  This 
complex process is governed by genetic mutation, 
which results in cancer cells losing their resemblance 
to the normal cells they are ultimately derived from, 
overcoming built-in cellular mechanisms to prevent 
runaway growth, inducing neoangiogenesis or the 
formation of new blood vessels, as well as eventual 
metastasizing to foreign tissue sites.1  Importantly, 
cancers develop an ability to evade the body’s im-
mune system through a variety of mechanisms, such 
as changing surface proteins that immune cells nor-
mally use to home in on foreign cells, accumulation of 
regulatory T-cells (Treg) that suppress the immune 
response, as well as secretion of specific immune sig-
naling cytokines (e.g., interleukin 6 [IL-6] and 10 [IL-
10]) to inhibit lymphocytes that normally kill tumor 
cells.2,3  So if cancer has developed an ability to sub-
vert the immune system, how is it possible to over-
come this mechanism of tumor self-preservation?  
The burgeoning field of immunotherapy may hold 
some answers in creating novel treatments for cancer 
as well as new ways of thinking about this old disease. 
 
The immune system is a complexity overcome by the 
cleverness of cancer cells.  This system has been clas-
sically divided into the innate and adaptive immune 
systems.2-4  The innate immune system is the first-line 
defense system involving anatomical barriers to infec-
tion, cytokine-mediated recruitment of immune cells, 
as well as complement proteins, (molecules used to 
identify and destroy foreign cells while recruiting im-
mune cells).  Other players in the innate immune sys-
tem include macrophages that ingest and destroy for-
eign cells, neutrophils that secrete destructive en-
zymes, basophils and eosinophils that aid in eliminat-
ing parasites, as well natural killer T-cells that target 
foreign cells, including tumor cells.  One of the ulti-
mate results of the innate immune system is the acti-
vation of the adaptive immune system via antigen 
presenting cells.  The adaptive immune system con-
sists predominantly of CD8+ cytotoxic T-cells that mon-
itor and destroy infected cells, CD4+ helper T-cells that 
identify foreign antigens to signal antibody produc-
tion, and B-cells that are involved in sensing antigens 
and forming antibodies.  This system also includes 
gamma/delta T-cells that share characteristics of CD8+ 
and CD4+ T-cells.  Despite each of these intricate, well-
regulated components, cancer cells have developed 
methods to overcome nearly every mechanism of the 
immune system. 
 
Cancer immunotherapy is broadly defined as the abil-
ity to induce the innate and adaptive immune system 
to neutralize neoplastic cells.  Multiple methods have 
developed over the past 50 years with the most inter-
esting clinical applications unveiled only recently.  
These include non-cellular methods such as antibod-
ies and drugs to regulate the immune system (Figure 
1) as well as cellular based techniques to manipulate 
the immune system such as adoptive cell transfer 
(ACT) and tumor vaccines (Figure 2).  These methods 
have shown mixed effects in different cancers again 
reaffirming the immense heterogeneity of cancer and 
difficulty in treating this disease. 
 
A straightforward strategy to treat cancer includes 
inducing the immune system. Administration of the 
body’s own signaling molecules (cytokines such as IL-
2 or interferon-α) has been shown to stimulate the 
immune system to fight cancer (Figure 1A).5  In fact, 
pegylated interferon-α2b was approved by the Feder-
al Drug Administration (FDA) in 2011 for the treat-
ment of melanoma.6  These initial approaches have 
been expanded by recent knowledge regarding im-
mune-modulating antibodies and cell signaling.  Tu-
mor-specific monoclonal antibody, generation is an 
approach that uses purified antibodies generated in 
the lab towards a specific tumor cell surface target.7 
Rituximab (Biogen Idec/Genentech, San Francisco, CA) 
is a monoclonal antibody used to target CD20 cell re-
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ceptors which has been approved by the FDA in the 
treatment of non-Hodgkin cell lymphoma and chronic 
lymphocytic leukemia, as well as several non-
oncological diseases.8  Recent studies have surprising-
ly shown that this antibody helps induce the immune 
system to kill targeted tumor cells in a process known 
as antibody-dependent cell-mediated cytotoxicity 
(ADCC) (Figure 1B).9  The drug Trastuzumab 
(Genentech, San Francisco, CA), also known as Her-
ceptin and used to target the Her2/Neu growth factor 
receptor in the treatment of breast cancer, has also 
been shown to mediate ADCC in addition to its well 
known effects on altering growth factor signaling of 
targeted cancer cells.10 
 
Other novel uses of monoclonal antibodies include 
immune-modulating antibodies.  Two new com-
pounds, Ipilimumab (Bristol-Myers Squibb, Princeton, 
NJ) and Tremlimumab (Pfizer, New York, NY), have 
been shown to target CTLA-4 (Figure 1C)11.  Normally 
CTLA-4 is a co-regulatory receptor on T-cells that 
binds to molecules B7-1 and B7-2 found on dendritic 
or tumor cells and inhibits the immune system, which 
can allow cancer cells to escape targeting.  Ipili-
mumab and Tremlimumab disrupt this inhibition and 
have shown response rates of 10-15% with metastatic 
melanoma and renal cell carcinoma.12  Ipilimumab 
has been FDA-approved as a first-line therapy for met-
astatic melanoma based on promising phase III tri-
als.13  Even newer therapies are looking at additional 
co-regulatory immune-checkpoint targets such as pro-
grammed cell death 1 (PD1) which are present in 
many cancers and may result in a more universal on-
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Figure 1: Non-cellular methods of immunotherapy. Various methods of immunotherapy using non-cellular 
means are shown.  A) Treatment with interleukin-2 (IL-2) or interferon-α can stimulate the immune system 
to fight cancer.  Examples include the use of pegylated interferon-α2b in the treatment of melanoma.  B) 
Designed tumor-specific monoclonal antibodies can target tumor cells via induction of an immune response 
(Antibody-mediated cell-dependent cytotoxicity) or via activation of the immune system’s complement cas-
cade (Complement activation).  Examples include Rituximab for the treatment of non-Hodgkin cell lympho-
ma and chronic lymphocytic leukemia as well as Trastuzumab in the treatment of breast cancer.  C) Im-
mune-modulating antibodies are used to target co-regulatory proteins that allow T-cells to interact with tu-
mor cells or antigen presenting cells.  Examples include Ipilimumab and Tremlimumab for the treatment of 
metastatic melanoma.  D) Antibody-drug conjugates and antibody-toxin conjugates are being developed to 
target tumor cells.  Antibody-radioisotope conjugates may allow for earlier tumor diagnosis.  Bispecific 
monoclonal antibodies are useful for localizing the body’s immune cells to tumor cells. 
 
cological therapy.6,14 The ability of bifunctional anti-
body-like molecules to bind cancer cells and retarget 
T-cells towards cancer cells (Figure 1D)15 or use anti-
body-drug/antibody-toxin conjugates to directly target 
individual cancer cells (Figure 1D)16 is also an area of 
open investigation.  Antibody-radioisotope conjugates 
have also been investigated as methods to diagnose 
tumors earlier as well as identify disease progression 
sooner than current modalities.  These methods sug-
gest that non-cellular based techniques to regulate the 
immune system can be potent ways of treating can-
cer.  
 
One form of immunotherapy that has gained momen-
tum in recent years includes adoptive cell transfer 
(ACT).  This technique utilizes anti-tumor T-cells that 
are manipulated ex vivo and then infused into a pa-
tient, in a similar method to bone marrow transplan-
tation.  In one study, tumor infiltrating lymphocytes 
obtained from patients, expanded ex vivo in a lab, 
and then re-infused in patients with metastatic mela-
noma showed that in addition to standard therapy, a 
clinical response of 34-72% was seen (Figure 2A).17  
Therapies using such multicellular treatments have 
shown greater efficacy than therapy with purified sin-
gle cells, again highlighting the heterogeneity of can-
cers and their surface markers in striving to achieve 
personalized therapy.18  However, the limitation of 
ACT involves the cumbersome cell-extraction process.  
Newer approaches utilize engineered T-cell receptors 
inserted into lab cultured CD4+ and CD8+ peripheral 
lymphocytes that can be transfused into patients.19  
ACT can achieve tumor-inhibiting activity so long as a 
patient’s tumor possesses the required target.  Combi-
nations of ACT treatments along with standard treat-
ments are being investigated in various early phase 
clinical trials for some cancers.20 
 
One of the most exciting avenues in immunotherapy 
is the development of cancer vaccines.  Initially set-
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Figure 2: Cell-based methods of immunotherapy towards cancers. Various methods of immunotherapy us-
ing cellular means are shown. A) Adoptive cell transfer (ADT) is demonstrated.  Tumor infiltrating lympho-
cytes are extracted from patients, expanded ex vivo in laboratory cultures, and reinfused back to patients.  
Engineered T-cells can also be generated in cultures before reinfusion.  B) Cancer vaccines are shown.  Tu-
mor cells are extracted from patients and specific tumor proteins are extracted before either being reinject-
ed into patients or used to sensitize patient-derived dendritic cells to target tumors.   Examples include 
Spuleucel-T used in the treatment of hormone-resistant prostate cancer. 
 
back by a variety of early clinical trial failures in the 
1960s, this approach has generated renewed interest 
along with a recent FDA-approved treatment.  Cancer 
vaccines involve the administration of tumor proteins 
to generate an immune response or immune cells (i.e. 
dendritic cells) sensitized to tumor proteins (Figure 
2B).  Spuleucel-T/Provenge (Dendreon, Seattle WA), 
FDA-approved in 2010 for the treatment of advanced 
hormone-resistant prostate cancer, involves inoculat-
ing patient-derived peripheral blood mononuclear 
cells with prostatic acid phosphatase linked to granu-
locyte macrophage colony-stimulating factor – essen-
tially training a patient’s own cells to target prostate 
cancer specifically.21  In phase III trials, Spuleucel-T 
resulted in a 4-month overall survival benefit; The 
cost of this treatment, however, has been estimated to 
be approximately $100,000, which may limit its even-
tual application.22  Vaccines towards melanoma23, 
high-grade glial24,25, breast26, pancreatic27, lung28 can-
cers are currently in development.  New knowledge of 
immune regulation in cancer has improved the effica-
cy of these approaches by using improved target anti-
gens, high quantities of antigens to sensitize immuni-
ty, and proper co-stimulatory signals to activate im-
mune cells. 
 
The field of immunotherapy is emerging significantly 
as a viable option in the treatment of cancer.  Much 
work has yet to be done before this dream can be-
come a reality for many patients.  In addition, new 
developments have dramatically altered the concept 
that cancers have unilaterally circumvented the im-
mune system.  Instead, various methods of inducing 
the immune system to fight cancer have been devel-
oped, methods which will hopefully act as precursors 
for the development of similar methods in the near 
future.   
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